share_log

Avenue Therapeutics | 8-K: Current report

SEC announcement ·  Jan 8 00:00
Summary by Moomoo AI
On January 5, 2024, Avenue Therapeutics, Inc., a specialty pharmaceutical company, announced the entry into warrant exercise agreements with existing accredited investors. The agreements pertain to the immediate exercise of outstanding warrants to purchase approximately 16.5 million shares of the company's common stock, which is expected to generate gross proceeds of about $5.0 million. The warrants include November 2023 Series B warrants and January 2023 warrants, with the latter's exercise price reduced from $1.55 to $0.3006 per share. The transaction is anticipated to close on or about January 9, 2024, subject to customary closing conditions. Avenue Therapeutics plans to issue new unregistered Series A and Series B warrants as consideration for the immediate cash exercise of the existing warrants. These new warrants will not be exercisable until stockholder...Show More
On January 5, 2024, Avenue Therapeutics, Inc., a specialty pharmaceutical company, announced the entry into warrant exercise agreements with existing accredited investors. The agreements pertain to the immediate exercise of outstanding warrants to purchase approximately 16.5 million shares of the company's common stock, which is expected to generate gross proceeds of about $5.0 million. The warrants include November 2023 Series B warrants and January 2023 warrants, with the latter's exercise price reduced from $1.55 to $0.3006 per share. The transaction is anticipated to close on or about January 9, 2024, subject to customary closing conditions. Avenue Therapeutics plans to issue new unregistered Series A and Series B warrants as consideration for the immediate cash exercise of the existing warrants. These new warrants will not be exercisable until stockholder approval is obtained to increase authorized shares and to comply with Nasdaq rules. The company has engaged Maxim Group LLC as the exclusive financial advisor and warrant solicitation agent for the transaction. Avenue Therapeutics intends to use the net proceeds for general corporate purposes and has committed to filing a registration statement with the SEC for the resale of the shares issuable upon exercise of the new warrants.

This announcement is a separate document:

Doc 1

Doc 2

Doc 3

Doc 4

Doc 5

Doc 6

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more